T-Cell Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

T-Cell Lymphoma Drug Profiles and Clinical Trials - Global Trends and Analysis Review, H2 2017 ... - Business Wire (press release)



T-Cell Lymphoma Drug Profiles and Clinical Trials - Global Trends and Analysis Review, H2 2017 ... 
Business Wire (press release)
This T- Cell Lymphoma clinical trials report provides comprehensive analysis and trends in global T- Cell Lymphoma disease clinical trials. The research work analyzes the evolution of T- Cell Lymphoma clinical trial trends across countries and regions ...

and more » 


CAR T-Cell Therapy Gets Priority Review for Lymphoma Treatment - Curetoday.com



Curetoday.com
 
CAR T-Cell Therapy Gets Priority Review for Lymphoma Treatment 
Curetoday.com
The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Kymriah (tisagenlecleucel) to be used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL ...
FDA Grants Priority Review to CAR T-Cell Therapy Tisagenlecleucel for DLBCL www.oncnursingnews.com/
Kymriah Granted Priority Review for Diffuse Large B-Cell Lymphoma Specialty Pharmacy Times
FDA Grants Tisagenlecleucel Priority Review for DLBCL OncLive
Markets Insider 
all 17 news articles » 


Kite, Pfizer to Assess Yescarta-Utomilumab Combination in Lymphoma - Genetic Engineering & Biotechnology News



Kite, Pfizer to Assess Yescarta-Utomilumab Combination in Lymphoma 
Genetic Engineering & Biotechnology News
Kite, a Gilead Company, and Pfizer said today they will assess a combination therapy for refractory large B-cell lymphoma that combines Kite's approved chimeric antigen receptor T-cell (CAR-T) treatment Yescarta? (axicabtagene ciloleucel) with Pfizer ...

and more » 


Winter Stresses the Importance of Identifying Risk Status in Follicular Lymphoma Patients - Targeted Oncology



Winter Stresses the Importance of Identifying Risk Status in Follicular Lymphoma Patients 
Targeted Oncology
Winter: I think immunotherapy is the most exciting area in general, not just for follicular lymphoma, but also for large cell lymphoma. There is very little data on CAR T-cell therapy in follicular lymphoma, but we know follicular lymphoma to be one of ...

 


FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma - Lymphoma News Today



Lymphoma News Today
 
FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma 
Lymphoma News Today
The U.S. Food and Drug Administration (FDA) will prioritize the regulatory review of Novartis' application to use Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Novartis hopes ...

and more » 


New Lymphoma CAR T-cell Therapy Production Method Improves ... - Lymphoma News Today



Lymphoma News Today
 
New Lymphoma CAR T-cell Therapy Production Method Improves ... 
Lymphoma News Today
A new method for growing the T-cells used in lymphoma immunotherapies may some day lead to treatments that are faster and do a better job of honing in on a specific target. A research team at two Harvard institutions developed a way to mimic signals ...
3D Bioscaffold Mimics Antigen-Presenting Cells for Improved T-Cell ... Genetic Engineering & Biotechnology News

all 3 news articles » 


Gilead/Kite team up with Pfizer for CAR-T-mAb combination - FierceBiotech



FierceBiotech
 
Gilead/Kite team up with Pfizer for CAR-T-mAb combination 
FierceBiotech
Yescarta (axicabtagene ciloleucel), approved by the FDA last year in the first wave of new CAR-T cell therapies, will be teamed up with Pfizer's experimental humanized 4-1BB agonist utomilumab in patients with refractory large B-cell lymphoma. The ...
Kite Announces Clinical Collaboration to Evaluate Investigational ... Business Wire (press release)
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo Endpoints News

all 3 news articles » 


EFS at 24 months stratifies outcomes in peripheral T-cell lymphoma - Healio



EFS at 24 months stratifies outcomes in peripheral T-cell lymphoma 
Healio
EFS at 24 months was a useful endpoint for stratifying outcomes among patients with peripheral T-cell lymphoma, study data showed. ?We previously used landmark analyses based on event-free survival to evaluate clinically useful end points in other ...

 


CAR T-cell therapies in treating lymphoma: Pros and cons - ModernMedicine



CAR T-cell therapies in treating lymphoma: Pros and cons 
ModernMedicine
Catherine Bollard, MD, director of the Center for Cancer and Immunology Research at Washington, D.C.-based Children's National Health System, discussed immunotherapy for non-Hodgkin's lymphoma at the 2017 American Society of Hematology (ASH) annual ...

 


Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma - GlobeNewswire (press release)



Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma 
GlobeNewswire (press release)
SEATTLE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has commenced patient dosing in a Phase 2 clinical ...

and more »